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Methyl-CpG-binding domain-2 (Mbd2) acts as an epigenetic regulator of gene
expression, by linking DNA methylation to repressive chromatin structure. Although
Mbd2 is widely expressed in gastrointestinal immune cells and is implicated in
regulating intestinal cancer, anti-helminth responses and colonic inflammation, theMbd2-
expressing cell types that control these responses are incompletely defined. Indeed,
epigenetic control of gene expression in cells that regulate intestinal immunity is generally
poorly understood, even though such mechanisms may explain the inability of standard
genetic approaches to pinpoint the causes of conditions like inflammatory bowel
disease. In this study we demonstrate a vital role for Mbd2 in regulating murine colonic
inflammation. Mbd2−/− mice displayed dramatically worse pathology than wild type
controls during dextran sulfate sodium (DSS) induced colitis, with increased inflammatory
(IL-1β+) monocytes. Profiling of mRNA from innate immune and epithelial cell (EC)
populations suggested that Mbd2 suppresses inflammation and pathology via control
of innate-epithelial cell crosstalk and T cell recruitment. Consequently, restriction of
Mbd2 deficiency to CD11c+ dendritic cells and macrophages, or to ECs, resulted in
increased DSS colitis severity. Our identification of this dual role forMbd2 in regulating the
inflammatory capacity of both CD11c+ cells and ECs highlights how epigenetic control
mechanisms may limit intestinal inflammatory responses.
Keywords: epigenetics, colitis, macrophage, epithelium, dendritic cell
INTRODUCTION
Epigenetic mediated changes in gene expression that are not encoded in DNA
sequence, and thus not accounted for using existing GWAS, represent an attractive
mechanism for explaining part of inflammatory bowel disease (IBD) susceptibility (1).
Epigenetic processes such as DNA methylation, histone modification and nucleosome
remodeling have all been shown to influence the regulation of key cell functions,
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GRAPHICAL ABSTRACT | Overview of Mbd2 deficient mice during DSS colitis.
including the immune response, and require the presence of
methyl-binding domain proteins (Mbds) to exert these effects
efficiently (2, 3). One of these, Mbd2, binds to methylated
DNA, recruiting a nucleosome remodeling deacetylase (NuRD)
complex that can significantly influence gene expression
(3). Mbd2 has been shown to play an important role in
gastrointestinal (GI) tract response to helminths and in
predisposition to colorectal malignancy (4, 5). In addition, we
have shown that Mbd2 deficient intestinal T cells over-express
IFN-γ in experimental colitis (6), that Mbd2 deficient mice
develop chronic intestinal inflammation after a single mucosal
injury (6), and Mbd2 deficient dendritic cells (DCs) are less
able to initiate immune responses (2). However, the mechanisms
underpinning these observations, and the range of GI tract
mucosal cells under the control of Mbd2, are poorly described.
Innate immune cells, particularly macrophages and DCs,
are essential to maintain a balanced response in the intestines
during health and inflammation. Macrophages, abundant in
the gut mucosa (identified as CD11b+F4/80+CD64+MHC-
II+Ly6C−{mice} or CD14+CD64+HLA-DRHiSIRPα+{human}),
are poorly responsive to Toll-like receptor (TLR) stimulation
and secrete large quantities of the regulatory cytokine IL-
10 in the steady state (7). However, this phenotype is
disrupted during inflammation, where macrophages are capable
of pro-inflammatory cytokine release that is in part controlled
by histone reader facilitated regulation of NF-kB response
elements (8).
Like macrophages, DCs are central to intestinal homeostasis,
with several intestinal subsets which differ in origin,
development and function (9). Murine cDC1s (identified
as CD11b−CD103+XCR1+), equivalent to CD103+Sirpα− DCs
in humans, are dependent on transcription factors (TFs) Id2,
Irf8, and Batf3 and induce anti-viral/bacterial IFNγ (Th1) CD4+
T cell responses (10). In contrast, CD11b+CD103+ intestinal
cDC2s are related to CD103+Sirpα+ DCs in human intestines,
depend on TFs Irf4 and Notch2 (10) and are important for
induction of IL-17 (Th17) and IL-4/IL-5/IL-13 (Th2) CD4+
T cell responses (11). Whether epigenetic gene regulation is
important in controlling immune responses of these subsets
in the gut is unknown. However, inhibition of histone reading
proteins in DCs in vitro causes failure of DC maturation and
DC-mediated antigen dependent proliferation of naïve T cells
(12, 13). Therefore, epigenetic regulation of gene expression
within these DC subsets is likely to be crucial for their functional
capability of mediating intestinal immunity.
In addition to DCs and macrophages, colonic epithelial cells
(CECs) play a key role in barrier integrity and immune responses.
ECs develop from pluripotent stem cells in the crypt niche,
functional plasticity of which is dependent upon epigenetic
proteins such as polycomb protein-mediated changes in histone
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FIGURE 1 | Expression of Mbd2 is vital to limit the severity of pathology during colitis. Mbd2−/− or littermate WT mice were co-housed and subjected to DSS in
drinking water, tissues were harvested 6 days post consecutive treatment. The severity of colitis in the mice was assessed by (A) representative colon gross
(Continued)
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FIGURE 1 | pathology, (B) weight loss following DSS treatment, and (C) symptom score (calculated from daily assessment of weight loss, rectal bleeding and stool
consistency). (D,E) colon sections obtained from the mice were stained with H&E and colitis severity was assessed blinded according to a DSS histo-pathology score.
(F,G) Colonic lamina propria cells were isolated and the relative proportion and number of monocytes, neutrophils, eosinophils, macrophages, and DC subsets were
assessed by flow cytometry. Lamina propria cells were incubated for 3 h with 1 µl/ml Golgistop and (H) the proportion of monocyte, neutrophil, eosinophil, cDC1s
(CD11b−CD103+) and macrophages that express IL-1β (I) the proportion of myeloid IL-1β+ cells (J), and the total number of IL-1β+ cells was assessed by
intracellular staining and flow cytometry. Mean symptom score ± SEM, representative data of 3 independent experiments (C) presented, all other graphs show least
mean square + SEM, n = 15–25 per group, analyzed by linear regression of 6 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, #
comparison of total number of myeloid cells DSS treated Mbd2−/− vs. WT (P < 0.0001).
modification. Indeed, altered histone motifs via HDAC1 and 2
inhibition cause barrier failure and susceptibility to colitis (14).
ECs also express anti-microbial products (such as calprotectin
and defensins), and may facilitate presentation of antigen via
MHC-I and -II (15), so are poised to co-ordinate downstream
immune responses, which may be in part reliant on epigenetic
control (4, 16).
In this work, we have discovered that Mbd2 acts as a
central regulator of intestinal inflammation. We found that the
severe inflammation that develops in Mbd2−/− mice during
DSS driven colitis (6) is accompanied by a large accumulation
of IL-1β+ monocytes. Although mRNA analysis of isolated
cells from Mbd2−/− mice revealed no intrinsic role for Mbd2
in colon monocyte gene regulation, this approach identified
dysregulated cDC1 andmacrophage expression of genes linked to
innate cell-CEC crosstalk and intestinal homeostasis. Strikingly,
restriction of Mbd2 deficiency to CD11c+ cells resulted in
an exacerbated IL-β+ monocyte mediated colitis. Further,
Mbd2−/− CECs displayed profound dysregulation of genes
controlling MHC, with EC-restricted Mbd2 deficiency resulting
in elevated intestinal CD8+ T cell responses. These data reveal an
epigenetic mechanism that is central to limiting excessive colonic
inflammation via two discrete processes and identify methyl-
CpG-binding proteins and the genes under their control as
potential therapeutic targets for intestinal inflammatory disease.
RESULTS
Mbd2 Is a Central Regulator of
Susceptibility to Colonic Inflammation
Assessment of Mbd2 distribution throughout the murine
small and large intestine using RT-qPCR showed that Mbd2
mRNA expression was higher in the large vs. small intestine,
and greater in the distal (rectum) vs. proximal (caecum)
colon (Supplementary Figure 1a). In addition, MBD2
mRNA levels were significantly reduced in active human
IBD (Supplementary Figure 1b). This tightly controlled GI
tract Mbd2 expression suggested that it may be an important
regulator of colon inflammation. To address this possibility,
we investigated how Mbd2 deficiency affected the colonic
response to inflammation. Naïve Mbd2−/− mice do not develop
spontaneous intestinal inflammation (17), maintained an intact
epithelial barrier and had equivalent levels of colon ifng/IFN-γ to
WT controls (Supplementary Figures 1c–e). Murine ingestion
of DSS causes intestinal barrier breakdown, exposing the
underlying mucosa to the microbiota, with resultant tissue
damage, diarrhea, weight loss, and rectal bleeding (17). In
keeping with our previous observations (6), the colons of DSS
treated Mbd2−/− mice displayed significantly worse pathology
than WT controls, with increased colon shortening, weight loss
and histopathology (Figures 1A–E).
As the role ofMbd2 inmyeloid cells in intestinal inflammation
is not known, we used multi-parameter flow cytometry (gating
strategy defined in Supplementary Figure 2) to assess these
populations in the colon lamina propria (LP). Proportions
of myeloid cell populations from naïve Mbd2−/− colon LP
were similar to WT mice (Supplementary Figures 3a,b). Upon
DSS challenge, the LP myeloid compartment of Mbd2−/−
mice had a significantly greater proportion of monocytes
(Ly6C+CD11b+MHC-II±) and neutrophils (CD11b+Ly6G+),
and less macrophages, compared toWT (Figure 1F). In addition,
total numbers overall of monocytes, neutrophils, macrophages,
and cDC1s were increased inMbd2−/− vs. WT (Figure 1G).
Myeloid cell secretion of pro-inflammatory cytokines,
particularly IL-1β, is a key factor in mediating intestinal
inflammation, with monocytes often a major source of this
cytokine (18). Analysis of colon myeloid cell ex vivo cytokine
production showed that naïveMbd2−/− mice had equivalent IL-
1β producing capabilities to WT as assessed by per cell, total cell
number, and overall proportion (Supplementary Figures 3c–e).
After DSS treatment, onlyMbd2−/− macrophages demonstrated
increased per cell IL-1β production (Figure 1H). However,
as Mbd2−/− LP displayed a marked proportional increase
in monocytes in response to DSS (Figures 1F,G), these cells
became the dominant source of IL-1β+ (Figure 1I). Moreover, as
myeloid cell numbers were greater in Mbd2−/− mice, increased
total numbers of IL-1β+ monocytes, neutrophils, eosinophils,
cDC1s, and macrophages were evident in the LP of DSS-treated
Mbd2−/− colon (Figure 1J). Thus,Mbd2was required to prevent
increased colonic inflammation involving augmented weight
loss, diarrhea, pan colitis, tissue architecture destruction, and
an immune cell infiltrate characterized by pro-inflammatory
cytokine secreting monocytes and neutrophils.
Mbd2 Deficiency in Monocytes Is Not
Associated With a Pro-inflammatory
Transcriptome
In mice, LP monocytes have similar marker expression to
blood monocytes (CD33, CD64, CD16, CX3CR1) but are potent
producers of pro-inflammatory cytokines IL-1β, IL-6, MMP-
1 and MMP-9 after stimulation with LPS, compared to other
monocyte subsets (19). Given the importance of these cells in
promoting inflammatory responses, and our observed increase in
IL-1β+ monocytes inMbd2−/− mice (Figure 1), we investigated
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FIGURE 2 | The impact of Mbd2 deficiency on mRNA expression by colon monocytes during colitis. Monocytes (CD11b+Ly6C+F4/80−MHC-II−/+) were isolated and
purified via FACS from the colon lamina propria of Mbd2−/− or WT littermate co-housed mice after 6 consecutive days of DSS treatment. RNA was extracted for
microarray mRNA expression analysis (5 biological replicates per genotype). (A) Volcano plot depicts differential gene expression profile of Mbd2−/− vs. WT
monocytes, with selected genes highlighted in red. Dashed lines represent P < 0.05, and ± 1-fold change. (B) Heat map of relative expression values for the
highlighted loci in (A) (log2 normalized intensity, one-fold change-filtered, P < 0.05). (C) Selected pathways from GOterm analysis of significantly altered mRNA
transcripts (P < 0.05) from (A), dashed line represents P < 0.05. (D) selected other non-significant loci based on literature review of monocyte-associated
inflammatory processes.
whether Mbd2 plays an intrinsic role in regulating monocytes
by analyzing the mRNA expression of purified colon monocytes
from DSS treated Mbd2−/− and WT mice. In total, only
7 genes (including Apoc1, Lyz1, and Vcam1, which encode
apolipoprotein C1, the bacteriocidal enzyme lysozyme and
the adhesion molecule Vcam1) were significantly dysregulated
(Log2 fold change ± 1, P < 0.05, all upregulated) when
comparingMbd2−/− monocytes toWT controls (Figures 2A,B).
Considering all significant (P < 0.05) genes irrespective of fold
change, GO term enrichment revealed upregulated pathways
in Mbd2−/− vs. WT monocytes that included “response to
TNF,” “response to LPS,” “response to bacterium,” and “defense
response” in the top10 most enriched items (Figure 2C).
However, the vast majority of loci associated with monocyte
pro-inflammatory ability (e.g., Il1a, Il1b, Il6, and Tlr2) were
unaffected by Mbd2 deficiency (Figure 2D). This suggests that
the elevated monocyte numbers in Mbd2−/− may not be due to
Mbd2 intrinsic regulation of their function and may instead be
a consequence of Mbd2 deficiency altering their recruitment or
retention in response to DSS.
Mbd2 Deficiency in CD11c+ Cells Confers
Increased Susceptibility to Colonic
Inflammation
We reasoned that influx of neutrophils and monocytes to the
colon might be limited by upstream cell populations under the
influence of Mbd2 mediated gene regulation. Macrophages and
DCs have both been implicated in DSS pathogenesis (20, 21)
with macrophages an important source of monocyte chemokines
such as CCL8 (22). Of the DC subsets, CD11b−CD103+
cDC1s which express bona fide DC TFs (23) and are crucial
for DSS pathogenesis via CEC crosstalk (24), were the only
expanded DC population in the absence of Mbd2 (Figure 1G).
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FIGURE 3 | Mbd2 regulates expression of both pro- and anti-inflammatory genes in cDC1 and macrophage populations during colitis. Colon lamina propria cDC1s
(CD11c+CD11b−CD103+) (A,B) and macrophages (CD11b+F4/80+MHC-II+Ly6C−) (C,D) were isolated from Mbd2−/− or WT littermate co-housed mice after 6
consecutive days of DSS treatment with RNA extracted for microarray mRNA expression analysis (2–5 biological replicates per genotype). (A,C) Volcano plot depicts
differential gene expression profile of Mbd2−/− vs. WT cDC1s (A) or macrophages (C), with selected genes highlighted in red. Dashed lines represent P < 0.05, and
±1-fold change. (B,D) Heat map of relative gene expression values from those highlighted loci in (A,C) (log2 normalized intensity, one-fold change-filtered, P < 0.05).
Similarly, macrophages were the most numerous LP myeloid
population (Supplementary Figure 3b) and the onlymyeloid cell
to significantly increase per cell production of IL-1β after DSS in
Mbd2 deficiency (Figure 1H).
Therefore, to understand whether cDC1 ormacrophageMbd2
deficiency was important for the increased susceptibility of
Mbd2−/− mice to DSS colitis, we performed microarray analysis
on purified CD11b−CD103+ DCs and macrophages from WT
and Mbd2−/− DSS treated mice. cDC1s from DSS treated
Mbd2−/− mice showed 27 significantly dysregulated genes (Log2
fold change± 1, P< 0.05, 10 up-, and 17 down-regulated) vs.WT
controls (Figures 3A,B). Ets2, the most significantly upregulated
locus in Mbd2−/− cDC1s, is a transcriptional regulator that
increases expression of miR-155, a potent pro-inflammatory
mediator found at increased levels in IBD mucosa (25, 26).
Gipc1 andAdcy4, also significantly upregulated inMbd2−/− DCs,
encode a GTPase activator protein for Gαi/Gαq and adenylate
cyclase enzyme, respectively, both of which can increase DC
cAMP levels (27). Of the genes downregulated inMbd2−/− DCs,
Nab1, and Itgae (CD103) may affect CEC function by reducing
STAT5 and E-cadherin signaling, respectively, that may pre-
dispose to epithelial barrier breakdown (28, 29). Considering
all significant (P < 0.05) genes irrespective of fold change,
GOterm pathway analysis revealed no immunological pathways
of note, though Ets2, Gipc1, and Adcy4 were all represented in
the “intracellular” pathway, which was also the most enriched
GOterm (P = 5.1× 10−7) (Supplementary Table 1).
Isolation and mRNA microarray analysis of macrophages
showed 41 significant genes were dysregulated (Log2 fold change
± 1, P < 0.05, 38 up-, and 3 down-regulated) in DSS treated
Mbd2−/− mice, compared to WT (Figures 3C,D). Mbd2−/−
colon macrophages displayed altered expression of genes
associated with both dampening pro-inflammatory responses
(Retnla and Ido1) and promoting bactericidal pathways (Lyz1), in
addition to epithelial wound healing (Trem2), vascular adhesion
(Vcam1, as also seen in Mbd2 deficient monocytes), and Fclrs
(a poorly described gene that has putative scavenger binding
domains) (30–33). However, as in DC GO term analysis,
there were no significantly dysregulated pathways of interest
(Supplementary Table 2).
Both macrophages and DCs in the colon express the integrin
CD11c, and depletion of CD11c+ cells using CD11c-DTR
mice may reduce or increase colitis severity, depending on
the presence or absence of the TLR9 agonist CpG (20, 21).
We thus restricted Mbd2 deficiency to CD11c expressing
cells using a CD11c-Cre+ Mbd2Fl/Fl system (CD11c1Mbd2)
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FIGURE 4 | CD11c+ cell expression of Mbd2 is essential to limit colitis. CD11c1Mbd2 or littermate Cre− (WT) mice were co-housed and tissues were harvested 8
days post consecutive treatment DSS treatment. The severity of colitis in the mice was assessed by (A) weight loss following DSS treatment and (B) symptom score
(Continued)
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FIGURE 4 | (calculated from daily assessment of weight loss, rectal bleeding, and stool consistency). (C) colon sections obtained from DSS treated mice were stained
with H&E and (D), colitis severity was assessed blinded according to a DSS histo-pathology score. Colonic lamina propria cells were isolated and the relative
proportion and number of monocytes, neutrophils, eosinophils, macrophages DC subsets (E,F) and T cells (J) were assessed by flow cytometry. Lamina propria cells
were incubated for 3 h with 1 µl/ml Golgistop and (G) the proportion of monocyte, neutrophil, eosinophil, cDC1s and macrophages that express IL-1β (H) the
proportion of myeloid IL-1β+ cells, (I) and the total number of IL-1β+ cells was assessed by intracellular staining and flow cytometry. (J) Number of CD4+ and
CD8α/β+ TCRα/β T cells as a proportion of CD45+ cells. (K) ifng mRNA levels derived from 1cm sections of distal colon in DSS treated CD11c1Mbd2 or littermate
Cre− mice determined by qPCR relative to gapdh. Mean symptom score ± SEM, representative data of 3 independent experiments (B) presented, all other graphs
show least mean square + SEM, n = 15–25 per group, analyzed by linear regression of 6 independent experiments, except (J,K) which are representative data from
3 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. # comparison of total number of myeloid cells DSS treated CD11c1Mbd2 vs. Cre−
controls (P < 0.0001).
(2). Although CD11c was expressed by a range of cell types
in the colon (Supplementary Figures 4a,b), >75% of colon
CD11c+ cells were either DCs (25%) or macrophages (50%),
with DC’s displaying the greatest per cell expression level
(Supplementary Figures 4a,b). Naïve CD11c1Mbd2 colon
LP displayed equivalent myeloid cell proportions, total cell
number and per cell IL-1β production, total IL-1β+ cell number
and overall proportion of IL-1β+ myeloid populations to
Cre− control mice (Supplementary Figures 5a–e). However,
CD11c1Mbd2 mice were significantly more susceptible to
DSS colitis than Cre− controls, displaying greater weight
loss, symptom score, and tissue architecture destruction
(Figures 4A–D). Due to an increased cellular infiltrate in
CD11c1Mbd2 DSS treated animals the number of monocytes,
neutrophils, eosinophils and macrophages was greater compared
to DSS treated Cre− mice (Figures 4E,F). Measurement of ex
vivo IL-1β production by myeloid cells showed that this was
equivalent for all populations in CD11c1Mbd2 and Cre− DSS
treated mice, with the exception of neutrophils (Figure 4G).
As such, the myeloid compartment was enriched for IL-1β+
neutrophils in CD11c1Mbd2 vs. Cre− DSS treated mice
(Figure 4H). Overall there were significantly more IL-1β+ cells
in CD11c1Mbd2 vs. Cre− controls after DSS, increased in
neutrophils, monocytes and eosinophils (Figure 4I). As Itgae
(CD103) downregulation was one the most significant effects
of Mbd2 deficiency in cDC1s (Figures 3A,B), we assessed
surface levels of CD103 on cDC1s (CD11b−CD103+) and
cDC2s (CD11b+CD103+) isolated from DSS treated Mbd2−/−,
CD11c1Mbd2, or control mice (Supplementary Figure 6). In
support of our microarray data (Figure 3), CD103 expression
showed a small but significant reduction on colon LP cDC1s
and cDC2s fromMbd2−/− mice (Supplementary Figures 6a,b).
In addition, when Mbd2 deficiency was restricted to CD11c+
cells, a subtle reduction in cDC1 CD103 expression was still
observed (Supplementary Figures 6c,d). Lastly, in contrast
to our previous work revealing a role for IFN-γ producing
CD4+ and CD8+ T cells in mediating colitis susceptibility in
global Mbd2 deficient mice (6), the total number of colon LP
CD4+ or CD8+ T cells and colon IFN-γ mRNA expression were
equivalent betweenDSS treated CD11c1Mbd2mice and controls
(Figures 4J,K), suggesting increased colitis susceptibility was T
cell independent in this context.
Collectively, these data show that CD11c-restricted Mbd2
deficiency resulted in increased severity of experimental colitis,
characterized by elevated infiltration of IL-1β producing
neutrophils and monocytes but equivalent numbers of LP T
cells and colon IFN-γ transcript. Colon cDC1s and macrophages
isolated from DSS treated Mbd2−/− mice also displayed altered
expression of genes associated with epithelial crosstalk (Trem2,
Nab1, Itgae) and inflammation control (Retlna, Ido1, Lyz1).
However, the increased inflammation evident in DSS exposed
CD11c1Mbd2 mice was less dramatic that in similarly treated
globalMbd2−/− mice (Figures 1A–J). This suggested that, while
Mbd2 expression in CD11c+ cells was important to limit
pathology, it also regulated gene expression in other, CD11c
negative, cell types to dampen inflammation during colitis.
Mbd2 Deficiency in Colon Epithelial Cells
Confers Increased Susceptibility to
Colonic Inflammation
Given that restriction ofMbd2 deficiency to CD11c+ cells did not
result in as severe inflammation as that seen in global Mbd2−/−
animals, and DSS is characterized by intestinal epithelial damage
(34), we speculated that CECs may represent an important cell
type that could be controlled byMbd2 during colitis.
To test this, we identified an EpCAM+CD45−Lin−
population of CECs [Supplementary Figure 7a, (35)] and
analyzed mRNA expression of FACS-purified cells by qPCR.
This revealed expression of EC-specific genes [intestinal stem
cell niche (Lrg5), goblet cell (Muc2), enteroendocrine (ChgA),
and colonocyte (Car1)] in addition to high levels of Mbd2
(Supplementary Figure 7b). To determine whether Mbd2
was critical for CEC regulation during inflammation, CECs
were isolated from DSS treated WT and Mbd2−/− mice and
mRNA expression assessed by microarray. Comparison of
Mbd2−/− to WT CECs revealed that 118 genes were significantly
dysregulated (Log2 fold change ± 1, P < 0.01, 75 up-, and
43 down-regulated), a more dramatic effect than was evident
in myeloid cells (Figure 5A and Supplementary Figure 8).
In CECs from DSS treated Mbd2−/− mice, there was a
striking up-regulation of MHC-I (including H2-Q8, H2-K2,
and H2-Q6), MHC-II (including H2-DMb1, H2-DMb2, and
H2-DMa), other MHC-related genes (including Cd74, Ciita,
Tap1/2, and Psmb8/9), and the T cell chemoattractant Cxcl9
(Figures 5A,B). At the same time, a significant decrease in levels
of expression of genes that promote epithelial barrier integrity
was also apparent (Cldn4, Krt36, and Actg2) (Figures 5A,B).
Considering all significant (P < 0.05) genes irrespective of fold
change, GO term enrichment revealed 366 significantly up-
regulated and 425 significantly down-regulated array features,
comparing Mbd2−/− vs. WT CECs, with numerous immune
cell function related pathways including “antigen processing
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FIGURE 5 | The impact of Mbd2 deficiency on mRNA expression by colon epithelial cells during colitis. (A) Volcano plot depicts differential gene expression profile of
mRNA as determined by microarray of colon epithelial cells (CD45− Lin− F4/80− CD3− EpCAM+) isolated by flow cytometry after 6 consecutive days DSS treatment
in Mbd2−/− or WT littermate co-housed mice. (B) Heat map of relative gene expression values from selected significant (log2 fold change ± 1, P < 0.05) loci and
selected up (C) and down (D) (P < 0.05) pathways from GOterm analysis from (A) (log2 normalized intensity, one-fold change-filtered, P < 0.05), 5 biological
replicates per genotype.
& presentation,” and “MHC protein complex,” (up-regulated)
and “cell adhesion,” “biological adhesion,” and “extracellular
matrix” (down-regulated) in the top10 most enriched terms
(Figures 5C,D). Together, this reveals that Mbd2 plays a
dominant role in controlling CEC mRNA expression during
intestinal inflammation.
We have previously shown that Mbd2 deficiency in ECs
using an inducible Cre model does not increase susceptibility
to colitis (6). However, we hypothesized this was due to
a modest reduction in EC Mbd2 expression using this
approach (∼20% reduction compared to WT levels), and
that further reductions in Mbd2 expression may be biologically
significant, given the profoundly altered transcriptome we
had observed in Mbd2-deficient CECs (Figure 5). Therefore,
we investigated CEC-restricted Mbd2 deficiency using a
constitutive Villin-Cre+ Mbd2Fl/Fl system (Villin1Mbd2)
(Supplementary Figure 9a) (35), where Mbd2 expression was
reduced by >99%, suggesting a superior level of EC-Mbd2
deficiency (Supplementary Figure 9a) (6). Naïve Villin1Mbd2
colon LP displayed equivalent myeloid cell proportions, total
cell number and per cell IL-1β production, total IL-1β+ cell
number and overall proportion of IL-1β+ myeloid populations
to Cre− control mice (Supplementary Figures 9b–f). As we
observed in DSS treated Mbd2−/− mice, CECs isolated from
naïve Villin1Mbd2 mice showed significant dysregulation of
genes associated with MHC-I and MHC-II (Cd74, H2-Ab1,
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FIGURE 6 | Epithelial cell expression of Mbd2 is vital to limit colitis. Villin1Mbd2 or littermate Cre− (WT) mice were co-housed and subjected to 2% DSS in drinking
water, tissues were harvested 8 days post consecutive treatment. The severity of colitis in the mice was assessed by (A) weight loss following DSS treatment and
(Continued)
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FIGURE 6 | (B) symptom score (calculated from daily assessment of weight loss, rectal bleeding and stool consistency). (C) colon sections obtained from DSS treated
mice were stained with H&E, and (D) colitis severity was assessed blinded according to a DSS histo-pathology score. Colon lamina propria cells were isolated and the
relative proportion and number of monocytes, neutrophils, eosinophils, macrophages, DC subsets (E,F) and T cells (J) were assessed by flow cytometry. Lamina
propria cells were incubated for 3 h with 1 µl/ml Golgistop and (G) the proportion of monocyte, neutrophil, eosinophil, cDC1s (CD11b−CD103+), and macrophages
that express IL-1β (H) the proportion of myeloid IL-1β+ cells, (I) and the total number of IL-1β+ cells was assessed by intracellular staining and flow cytometry. (J)
Number of CD4+ and CD8α/β+ TCRα/β T cells as a proportion of CD45+ cells. (K) ifng mRNA levels derived from 1cm sections of distal colon in DSS treated
VillinCre1Mbd2 or littermate Cre− mice determined by qPCR relative to gapdh. All graphs show least mean square ±SEM, n = 15–25 per group, analyzed by linear
regression of six independent experiments, except (J,K) which are representative data from three independent experiments. *P < 0.05, **P < 0.01, ****P < 0.0001.
H2-Dmb1), strongly suggesting that Mbd2 directly regulates
CEC immunogenicity (Supplementary Figure 10).
Following DSS treatment, Villin1Mbd2mice developed more
severe colitis than littermate Cre− controls, as demonstrated by
increased weight loss, symptom score and tissue architecture
destruction (Figures 6A–D). However, in contrast to DSS-treated
globalMbd2−/− and CD11c1Mbd2mice, Villin1Mbd2 animals
had similar proportions of myeloid cells to WT controls and did
not demonstrate either increased total numbers (Figures 6E,F),
IL-1β+ populations (Figures 6G–I), or cDC1 CD103 expression
(Supplementary Figure 11), that we observed in Mbd2−/− and
CD11c1Mbd2mice.
We have previously shown that DSS treated Mbd2−/− colon
LP CD4+ and CD8+ TCRα/β+ cells produce greater levels of
IFN-γ, and therefore reasoned that increased Mbd2−/− and
Villin1Mbd2CECMHC-II expressionmay affect T-cell function.
Indeed, one of the most up-regulated genes in Mbd2−/− CECs
during DSS was the T-cell chemokine Cxcl9 (Figure 5A), CEC
sources of which have been shown to correlate with IBD severity
(36). To support this, colon LP Mbd2 sufficient CD8α/β+ T cells
fromDSS treatedVillin1Mbd2mice were significantly expanded,
with corresponding increased levels of tissue IFN-γ transcript,
mirroring our previously reported work in Mbd2−/− mice
(Figures 6J,K) (6). In summary, these data suggest that Mbd2
plays a dual role in limiting experimental colitis by regulating
both CD11c-mediated myeloid cell, and CEC-mediated CD8+
T-cell, colon infiltration.
DISCUSSION
Intestinal surfaces are constantly exposed to a range of micro-
organisms, requiring tight regulation of host cells to prevent
over-exuberant immune responses that can lead to damaging
inflammatory pathology (37). However, our understanding of
how epigenetic processes affect immune-mediated intestinal
inflammation and disease is currently limited (1). Here we
show that expression of Mbd2, an epigenetic regulator of gene
transcription, by both CD11c+ innate cells and ECs is crucial for
limiting colonic inflammation.
In the steady state, Mbd2−/− mice showed similar barrier
integrity, absence of spontaneous inflammation and composition
of the LP myeloid compartment to littermate controls
(Figures 1A–C,E, Supplementary Figures 1c, 3). However,
following epithelial disruption via DSS treatment, Mbd2−/−
mice displayed dramatically worse pathology, with severe weight
loss, symptom score and immune infiltrate into the colon
(Figures 1A–G). Indeed, the myeloid compartment of DSS
treated Mbd2−/− mice was defined by an enrichment of pro-
inflammatory cell types, in particular an increased proportion
of IL-1β expressing monocytes and neutrophils (Figures 1H–J).
Monocytes are a key pro-inflammatory cell in human andmurine
colitis (18, 19, 38, 39), however colon monocytes isolated from
Mbd2−/−mice displayed dysregulation of only a handful of genes
and similar per-cell cytokine producing capabilities compared to
controls (Figures 2A,B,D). This suggested that increased tissue
numbers of these cells represented a consequence, rather than
cause, of increased colonic inflammation in Mbd2−/− mice.
We thus investigated other cellular sources of Mbd2 that could
account for this exacerbated pathology.
cDC1s have been shown to express DC-specific transcription
factors, migrate to MLNs in a CCR7 dependent manner, and
interact with CECs to limit colitis pathlogy (10, 24), yet
little is known about how epigenetic processes may regulate
their function. We observed that Mbd2−/− cDC1s significantly
upregulated expression of Ets2 (Figures 3A,B), a transcription
factor that controls the induction of miR-155 (25, 40). miR-155
has been shown to be a potent pro-inflammatory mediator found
at increased levels in the mucosa of IBD patients, suppressing
SOCS1 and negative inhibitors of TLR4, thereby increasing IL-6
and IL-8 from immune cells including intestinal myofibroblasts
(40, 41). Two other genes significantly upregulated in Mbd2−/−
cDC1s were Gipc1 and Adcy4 (Figures 3A,B), both of which can
increase cellular cAMP65−67. Increases in cAMP can interfere
with DC induction of Th2 responses, reduce MHC-II production
and impair antigen presentation capabilities (27, 42). However,
future dedicated investigation and validation of the function of
these genes in DCs, and determining whether these are regulated
by the action of Mbd2, may shed light on the downstream
mechanisms that influence intestinal pathology during colitis.
Murine colon macrophages are important mediators of
tolerance to the intestinal microbiota, with their depletion by
removing Ccr2+ monocyte precursors resulting in increased
susceptibility to chronic colitis (43). Comparison of WT and
Mbd2−/− cDC1 and macrophage gene expression revealed that
both cell types displayed dysregulated expression of mediators
associated with CEC crosstalk. Specifically, cDC1s from DSS
treated Mbd2−/− mice showed reduced levels of Itgae/CD103
[which interacts with CEC E-cadherin to prevent epithelial
shedding and boost CEC maturation (28)] and Nab1 [a co-
repressor of early growth response 2 (Egr2) (44), defects
in which result in reduced Stat5 signaling and increased
susceptibility to γ-irradiation intestinal injury (29, 45)]. This was
mirrored in reduced CD103 protein expression inMbd2−/− and
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CD11c1Mbd2 cDC1s (Supplementary Figure 6). Furthermore,
Trem2 downregulation, which has been implicated in colonic
epithelial repair during acute injury (32), was evident in
Mbd2−/− macrophages. Together, this suggested a role for Mbd2
in the regulation of gene expression in two important CD11c+
innate intestinal populations, with dysregulated expression of
genes implicated in CEC crosstalk.
To test the relevance of these observations, we utilized CD11c-
restricted Mbd2 depletion (CD11c1Mbd2 mice), which resulted
in increased susceptibility to DSS colitis compared to Cre−
controls (Figures 4A–D). Mechanistically, Mbd2 expression
by CD11c+ cDC1s or macrophages regulated basic cellular
processes such as antigen presentation and epithelial cross-
talk, and CD11c-restricted Mbd2 depletion was accompanied
by in an increase in IL-β+ monocyte recruitment. However,
the severity of colitis observed in CD11c1Mbd2 mice did
not reach the same level as that evident in globally deficient
Mbd2−/− mice (Figures 1B,C), so we sought to assess the role
for Mbd2 in CD11c− cell types that might explain increased
colitis susceptibility.
CECs regulate GI tract immunity by forming a physical
barrier, producing anti-microbial products such as defensins
and calprotectin (14), present antigen via MHC-II and secrete
cytokines such as IL-10, TGF-β, and IL-12p70 (46). The
differential expression of genes implicated in CEC-crosstalk from
Mbd2−/− cDC1s and macrophages (Figures 3A–D), suggested
Mbd2 may have direct and/or indirect roles in influencing CECs
during colonic inflammation. Indeed, our mRNA expression
dataset revealed that Mbd2−/− CECs displayed marked up-
regulation of genes associated with MHC-I and -II. MHC
molecules are found at increased levels on CECs in active
IBD, with MHC-II controlled by a transcriptional complex
that includes the master transactivator, Ciita (47). Like Mbd2,
the Ciita transcriptional regulator HIV Tat-interacting protein
[HTAPIP, aka K(lysine) acetyltransferase 5 (Kat5)], alters histone
acetylation, which in turn regulates chromatin remodeling,
signal transduction, and Tat mediated MHC expression (48). In
addition, EC deletion of histone deacteylase (Hdac) 1 and 2 or
3 in mice has been implicated in determining the overall pre-
disposition to intestinal pathology (12, 35). We also observed
reduced surface CD103 protein on cDC1s from Mbd2−/−
and CD11c1Mbd2, but not Villin1Mbd2, mice. CD103 (αEβ7
integrin) affects lymphocyte dendrite formation and motility
in a ligand dependent fashion, and interacts with E-cadherin
on ECs, deletion in which results in spontaneous colonic
inflammation and death due to increased EC shedding and lack
of EC maturation (25). Thus, Mbd2 may be required to support
local colon DC-EC interactions, through CD103-E-cadherin
interactions in these respective cell types.
Lastly, we observed equivalence in pro-inflammatory myeloid
cells in EC-restricted Mbd2 deficient colitis, but increased
Mbd2−/− CEC expression of T-cell chemokine Cxcl9. It is
possible that the increased colitis severity evident in global
Mbd2−/− vs. CD11c1Mbd2 or Villin1Mbd2 mice was due to
the additive pathology of IFN-γ+ T-cell recruitment driven
by Mbd2-deficient ECs. In support of this, we observed
expansion of CD8+ T-cells in DSS treated Villin1Mbd2, but
not CD11c1Mbd2, where CECs were Mbd2 sufficient. Indeed,
we have previously shown that Mbd2 deficient colon LP T
cells may overexpress IFN-γ and IL-17 (6). Future co-culture
experiments using Mbd2 sufficient/deficient CECs, T cells, DCs
or macrophages would be a useful approach to address the
relative importance of Mbd2 expression by each cell type in a
more reductionist in vitro setting.
Thus, in a combined model of Mbd2−/− colitis susceptibility
(Graphical Abstract), we speculate that at the onset of
intestinal inflammation, the Mbd2 deficient epithelium leads
to further intestinal damage, through Cxcl9 driven CD8+
T-cell recruitment and EC-MHC-II upregulation. Mbd2
deficient cDC1s facilitate this process by reduced CEC support
(reduced Itgae/CD103 and Stat5 signaling) and expression
of pro-inflammatory (mir-155 pathway) TFs. Mbd2 deficient
macrophages compound reduced CEC repair (reduced Trem2
expression), whilst simultaneously attempting to limit excessive
inflammatory processes (increased Ido1 and reduced Retlna).
The end result is profound IL-1β+ monocyte accumulation
facilitated by Mbd2 deficient CD11c+ cells, with simultaneous
accumulation of CD8+ T-cells that increases tissue IFN-γ due to
dysregulated, Mbd2 deficient, ECs.
In summary, Mbd2 is required for limiting colitis severity
via the regulation of both myeloid and epithelial responses in
the colon, employing multiple layers of cellular control that
cumulatively prevent excessive inflammation in the intestines.
Future work will focus on the role of DNA binding and
chromatin accessibility in the ability of Mbd2 to regulate
the function of cDC1s, macrophages and ECs. Strategies to
target Mbd2 for prevention of DC, macrophage/monocyte, or
CEC exacerbation of intestinal inflammation may enable future
development of innovative therapies to help control excessive
inflammatory responses that define conditions such as IBD.
METHODS
Mice
Mbd2−/− and CD11c1Mbd2 mice on a C57BL/6 background
were bred in-house and maintained under specific pathogen-
free conditions in the Faculty of Biology, Medicine and
Health, University of Manchester, in compliance with the
UK Home Office Animals (Scientific Procedures) Act 1986.
Villin1Mbd2 mice were generated by crossing Mbd2fl/fl with
Villin-Cre+ mice as previously described (2, 35). Age and sex
matched mice (aged 8–22 weeks) were used in the experiments.
CECs from Villin1Mbd2 mice displayed a >98% reduction
in Mbd2 transcript compared to littermate Cre− controls
(Supplementary Figure 9a).
DSS Model
Mice received 2% DSS salt b/w (reagent grade MW 36,000–
50,000 kDa; MP Biomedicals) ad libitum in sterile drinking water
for 6 days as described previously (49). Mice were monitored
daily for change in weight, rectal bleeding and diarrhea to
generate a symptom score. Experimental mice, wherever possible,
were co-housed from birth with littermate controls. In histology
analysis, the most distal 1 cm of colon was used for consistency
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between experiments, placed in 10% neutral buffered formalin
for 24 h before being transferred to 20% ethanol. Samples were
processed using standard hematoxylin and eosin (H&E) stain
before being scored blinded using an established DSS histo-
pathology protocol (50).
Cell Isolation
LP cells were obtained from mouse colon by enzymatic digestion
as described previously (49). Briefly the large intestines of mice
were excised and soaked in ice cold PBS, before removing
excess fat and feces, opened longitudinally and washed in
Hank’s balanced salt solution (HBSS; Sigma) 2% fetal calf
serum (FCS; Sigma) before being cut into 0.5 cm sections. A
further HBSS containing 2mM EDTA (Gibco) wash step was
used to remove mucous before digestion in complete RPMI
(cRPMI) (2mM L-glutamine{Gibco}, RPMI 1640, 100µg/ml
penicillin, 100µg/ml streptomycin and 10% FCS, {all Sigma})
containing 0.5 U/ml Liberase TM and 0.1 mg/ml Type IV DNAse
from bovine pancreas (both Sigma) for 45min in a shaking
incubator at 180 rpm, 37◦C. Cells were then washed in cRPMI,
passed through a 40-µM cell strainer (Thermo Fisher Scientific)
with the aid of a syringe plunger before resuspension to the
required concentration.
Flow Cytometric Analysis and Sorting of
Cells
Processed single cell suspensions [0.5–2 × 106 cells per
stain] were stained first using LiveDead blue (Invitrogen)
at a 1:2,000 dilution in 10 µl PBS for 10min at room
temperature then FcR-Block (2.4G2), followed by the antibodies
listed in Supplementary Table 3 at 4◦C for 30min, before
being fixed in 1% paraformaldehyde prior to acquisition as
described previously (51). To detect intracellular cytokines,
cells were incubated in cRMPI at 37◦C in 5% CO2 for 3 h
in the presence of 1 µl/ml GolgiStop (BD Biosciences). For
intracellular staining after fixation in 1% paraformaldehyde, cells
were permeabilized using Cytofix/Cytoperm (BD Biosciences)
or FoxP3 Transcription Factor buffer kit (ThermoFisher)
and incubated with intracellular antibodies for 1 h at 4◦C
(Supplementary Table 3). Cells were washed prior to sample
acquisition. All stained samples were acquired using a BD
Fortessa (BD Biosciences) and analyzed using FlowJo v.9
software (TreeStar). Flow cytometer photomultiplier tube
voltages were applied to ensure best compensation whilst
aligning to the latest cytometer setup and tracking settings.
The number of myeloid cells per mouse colon was determined
by calculating the proportion of identified populations in
Live/singlet/intact/CD45+/Lineage− cells, myeloid population
data was then expressed per mouse colon using the total LP cell
count derived after purification.
Colon LPCD45+Ly6G−Siglec-F−CD11b+Ly6C+monocytes,
CD45+Ly6G−Siglec-F−CD11b+Ly6C−MHC-II+F4/80+
macrophages, CD45+Ly6G−Siglec-F−CD11b−CD11c+CD103+
cDC1s and EpCAM+CD45−CD3−F4/80− from WT or
Mbd2−/− mice after 6 days of DSS treatment were FACS-purified
using a BD Influx 70µm nozzle size at 60PSI. Cell purity was
confirmed at >95% before processing for RNA isolation and
microarray analysis.
mRNA Microarray and Quantitative PCR
(qPCR)
Formurine colon/spleen tissue samples or sorted cell populations
total RNA was extracted using an adapted protocol (52) of the
mirVana miRNA isolation kit (Thermofisher). RNA quality was
assessed using Agilent RNA 6000 Pico assay, RNA integrity
number (RIN) >8.5 was considered satisfactory for subsequent
microarray analysis. For microarrays, RNA was labeled using
TotalPrep RNA amplification kits (Life Technologies) and
hybridized with Illumina MouseWG-6BeadChip arrays with
2–5 biological replicates (1–10 mice per replicate) from
three separate experiments of FACS-purified populations as
described above. All analyses were conducted in R using
Bioconductor. Pairwise group comparisons were undertaken
using linear modeling. Subsequently, empirical Bayesian analysis
was applied, including vertical (within a given comparison)
P-value adjustment for multiple testing, which controls for
false-discovery rate, using the limma Bioconductor package.
An adjusted P < 0.01 and absolute log base2 fold change
≥1.0 was taken to screen candidate genes for further analysis.
Functional enrichment analyses were performed for GO terms
using the appropriate packages. Focused “genes of interest”
lists were assembled from the literature and other publicly
available resources.
To measure gene expression of whole tissue (1 cm
section of distal colon or spleen was placed in 500 µl of
RNALater and kept on dry ice before storage at −80◦C)
or purified cells by RT-qPCR, complementary DNA of
extracted RNA was generated using SuperScript-III and
Oligo-dT (Life Technologies). Relative quantification of
genes of interest was performed by qPCR analysis using
QuantStudio 12 Flex Real Time PCR system, with Fast SYBR R©
Green Master Mix (Life Technologies), compared with a
serially diluted standard of pooled complementary DNA.
Expression was normalized to Gapdh. Primers are listed in
Supplementary Table 4.
FITC Dextran Intestinal Permeability Assay
Naïve Mbd2−/− and littermate controls were gavaged with
4 kDa FITC dextran at 60 mg/100 g body weight with
serum obtained 4 h post-gavage, concentrations determined by
spectrofluorophotometer (490/525 nm).
Colon Explant Supernatant Analysis
One cm sections of distal colon were removed and incubated
for 24 h in 1ml cRPMI. Cytokine concentrations in culture
supernatant was derived by cytokine bead array (BD biosciences).
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism
v.7 or JMP v.12 (SAS Institute). The data were checked to
confirm normality and that groups had equal variance. One-way
analysis of variance (ANOVA) with Tukey’s multiple comparison
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tests was employed to determine significant differences between
sample groups. Results from these tests were reported as
significant if P ≤ 0.05, with results from these tests shown
as mean ±SEM. For some experiments statistical analysis was
carried out using JMP, in which case data were analyzed
using three-way full-factorial fit models to assess effects such
as “genotype,” “treatment,” and “experiment” on the response
variable of interest. This allowed the interaction between effects
to be taken into account in addition to their impact on the
response variable, which enabled experimental repeats to be
pooled increasing the power of the analysis (53). The least squares
mean results table from the three-way full-factorial analysis
was used to test the contrast between specific experimental
groups using a joint F-test. A difference between experimental
groups was taken to be significant if the P-value (Prob > F)
was ≤0.05, with results in graphs shown as least squares mean
± SEM.
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